Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end‐stage renal disease

• Main Authors: Ryota Tanaka (Author), Yosuke Suzuki (Author), Hiroshi Watanabe (Author), Takashi Fujioka (Author), Kenshiro Hirata (Author), Toshitaka Shin (Author), Tadasuke Ando (Author), Hiroyuki Ono (Author), Ryosuke Tatsuta (Author), Hiromitsu Mimata (Author), Toru Maruyama (Author), Hiroki Itoh (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Because tacrolimus is predominantly metabolized by CYP3A, the blood concentration/dose (C/D) ratio is affected by CYP3A5 polymorphism. Parathyroid hormone (PTH) expression increases in secondary hyperparathyroidism, which is frequently associated with end‐stage renal disease. Recently, PTH...